This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


Scientists demonstrate a combination treatment can increase human insulin-producing cells in vivo

Credit: CC0 Public Domain

In preclinical studies, a team of researchers from Mount Sinai Health System in New York City and City of Hope in Los Angeles report new findings on a therapeutic combination that regenerated human insulin-producing beta cells, providing a possible new treatment for diabetes. The findings were published in Science Translational Medicine.

This work, led by Andrew F. Stewart, MD, Irene and Dr. Arthur M. Fishberg Professor of Medicine and Director of the Mount Sinai Diabetes, Obesity and Metabolism Institute, began at the Icahn School of Medicine at Mount Sinai in 2015. The studies were a team effort.

Adolfo Garcia-Ocaña, Ph.D., formerly a professor at Mount Sinai and who is now at City of Hope, a leading research center for and one of the largest cancer research and treatment organizations in the United States, and is the Ruth B. and Robert K. Lanman Chair in Gene Regulation and Drug Discovery Research and chair of the Department of Molecular & Cellular Endocrinology, and his research team designed the studies and performed the novel, extensive and detailed animal transplant and drug treatment models using from donors.

Final studies took place at City of Hope in 2023.

For the study, the natural product harmine, which is found in some plants, was combined with a widely used class of type 2 diabetes therapy called GLP1 receptor agonists.

Researchers transplanted a small number of human beta cells into mice that had no and that also served as a standard model of type 1 and type 2 diabetes; these mice were treated with the combination therapy and their diabetes was rapidly reversed. Strikingly, human beta cell numbers increased by 700% over three months with this drug combination.

"This is the first time scientists have developed a drug treatment that is proven to increase adult human beta cell numbers in vivo. This research brings hope for the use of future regenerative therapies to potentially treat the hundreds of millions of people with diabetes," said Dr. Garcia-Ocaña, the paper's corresponding author.

"It has been remarkable to watch this story unfold over the past 15 years," said Dr. Stewart, who, along with Peng Wang, Ph.D., Professor of Medicine (Endocrinology, Diabetes and Bone Disease) at Icahn Mount Sinai, conceived of and performed the initial high-throughput drug screen that led to the discovery of harmine described in Nature Medicine in 2015.

"The steady progression from the most basic human beta cell biology, through robotic drug screening and now moving to , illustrates the essential role for physician-scientists in academia and pharma."

Growing new beta cells

More than 10% of the world's adult population has diabetes, a disease defined by high blood sugar levels. In both type 1 and type 2 diabetes, a reduction in both the quantity and quality of insulin-producing beta cells causes high blood sugar. Unfortunately, none of the many commonly used diabetes therapies are able to increase human beta cell numbers, and therefore cannot completely reverse diabetes.

Fortunately, most people with diabetes have some residual beta cells, which is what inspired the research team to search for ways to restore their numbers.

The team had previously shown that several different inhibitors of an enzyme in beta cells called DYRK1A can induce the proliferation of adult human beta cells in a tissue culture dish for a few days. But prior to this study, no one had shown the ability to expand human beta cells numbers in vivo in human islet grafts used in an animal model over many months.

To accurately measure the mass of human beta cells in the islet grafts, the team turned to Sarah A. Stanley, MBBCh, Ph.D., Associate Professor of Medicine (Endocrinology, Diabetes and Bone Disease), and Neuroscience, at Icahn Mount Sinai.

Using an advanced laser microscopy tool called iDISCO+ that effectively makes biological tissue transparent, Dr. Stanley saw that beta cell mass was dramatically increased through mechanisms that included enhanced proliferation, function, and survival of the human beta cells. The technology allowed for accurate and rigorous quantitative assessment of engrafted human beta cells for the first time.

Translating results to the clinic

The Mount Sinai team recently completed a Phase I clinical trial of harmine in healthy volunteers to test its safety and tolerability. At the same time, Robert J. DeVita, Ph.D., Professor of Pharmacological Sciences and Director of the Marie-Josée and Henry R. Kravis Drug Discovery Institute at Mount Sinai, has developed next-generation DYRK1A inhibitors.

Mount Sinai is conducting studies to test these in humans for potential toxicity risks and estimate dosing for clinical trials, and is planning to initiate first-in-human trials with independent research teams next year. Mount Sinai owns an extensive patent portfolio covering these technologies.

Researchers also want to address the fact that in patients with type 1 diabetes, the immune system will continue to kill new beta cells. At City of Hope, Dr. Garcia-Ocaña and colleague Alberto Pugliese, MD, Samuel Rahbar Chair in Diabetes & Drug Discovery, chair of the Department of Diabetes Immunology, and director of The Wanek Family Project for Type 1 Diabetes within the Arthur Riggs Diabetes & Metabolism Research Institute, plan to test inducers of beta cell regeneration together with immunomodulators that regulate the immune system.

Their goal is for the combination to allow new beta cells to thrive and improve insulin levels.

"Our studies pave the way for moving DYRK1A inhibitors into human clinical trials and it's very exciting to be close to seeing this novel treatment used in patients," Dr. Garcia-Ocaña said. "There is nothing like this available to patients right now."

Drs. Stewart and DeVita are named co-inventors on patent applications for DYRK1A inhibitors, such as harmine, for the treatment of diabetes. These are filed through the Icahn School of Medicine at Mount Sinai and are currently unlicensed.

More information: Carolina Rosselot et al, Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system, Science Translational Medicine (2024). DOI: 10.1126/scitranslmed.adg3456.

Citation: Scientists demonstrate a combination treatment can increase human insulin-producing cells in vivo (2024, July 10) retrieved 17 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Team discovers new drug combo to induce high rates of human beta cell regeneration


Feedback to editors